Anemia response to Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) versus Epoetin Alfa (Eprex) in patients with chronic Kidney disease on Hemodialysis
Article Sidebar
Main Article Content
Abstract
Objective: Anemia, a common complication of chronic kidney disease, usually develops because of erythropoietin deficiency. Maintaining target hemoglobin (Hb) with minimal variability is a challenge in hemodialysis (HD) patients. The aim of this study is to compare the long- and short-acting erythropoietin erythropoietin stimulating agents such as Mircera and Eprex in achieving these targets.
Results: The response rate in the evaluation period was higher in patients treated with methoxypolyethylene glycol-epoetin beta (Mircera) than with epoetin (Eprex) alfa: 36 of 50 (72%) mean Hb concentration (10.51g/dl) versus 29 of 50 (58%) mean Hb concentration (9.81), with statistically significant p-value <0.0001.
Conclusion: Treatment with (Mircera) administered intravenously once monthly was superior to treatment with (Eprex) administered subcutaneously three times weekly for maintaining haemoglobin concentrations in patients with chronic kidney disease on hemodialysis.
Article Details
Copyright (c) 2017 Dhayef AK, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The Journal of Clinical Nephrology is committed in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. In order to use the Open Access paradigm to the maximum extent in true terms as free of charge online access along with usage right, we grant usage rights through the use of specific Creative Commons license.
License: Copyright © 2017 - 2025 | 
Open Access by Journal of Clinical Nephrology is licensed under a Creative Commons Attribution 4.0 International License. Based on a work at Heighten Science Publications Inc.
With this license, the authors are allowed that after publishing with the journal, they can share their research by posting a free draft copy of their article to any repository or website.
Compliance 'CC BY' license helps in:
| Permission to read and download | ✓ |
| Permission to display in a repository | ✓ |
| Permission to translate | ✓ |
| Commercial uses of manuscript | ✓ |
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
Anía BJ, Suman VJ, Fairbanks VF, Rademacher DM, Melton LJ. Incidence of anemia in older people: an epidemiologic study in a well defined population. J Am Geriatr Soc. 1997; 45: 825-831. Ref: https://goo.gl/tCC1mN
Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, et al. Definition and classification of chronic kidney disease: A position statement from kidney disease improving global outcomes (KDIGO). Kidney Int. 2005; 67: 2089-2100. Ref.: https://goo.gl/i6g9Qi
Kidney Disease Improving Global Outcomes. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: Summary of Recommendation Statements. Kidney Int. 2013; 84: 5-14.
Okada TS, Yanai MK, Takahashi S. The Kidney Early Evaluation Program (KEEP) of Japan: Results from the initial screening period. Kidney Int. 2010; 77: 17-23. Ref.: https://goo.gl/HDm4cr
Goddard J, Turner A. Kidney and urinary tract disease, Davidson’s Principles and Practice of Medicine. 22th ed. NewYourk: Brian R. Walker Elsevier. 2014; 488.
Bargman JM, Karl S, Joanne M. Chronic kidney disease, disorders of the kidney and urinary tract, Dennis L. Stephen L, (editors). Harrison principle of internal medicine. 19th edition. 2015; 1818-1826. Ref.: https://goo.gl/rC3dz8
Macdougall I, Eckardt K. Novel strategies for stimulating erythropoiesis and potential new treatment for anemia. Lancet. 2006; 368: 947-953. Ref.: https://goo.gl/Fh2LNP
Strippoli G, Manno C, Schena F, Craig JC. Haemoglobin and haematocrit targets for the anaemia of chronic renal disease. Cochrane Database Syst Rev. 2003; 1. Ref.: https://goo.gl/bs1DTk
Collins A, Li S, Peter W, Ebben J, Roberts T, et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol. 2001; 12: 2465-2473. Ref.: https://goo.gl/y5FiDP
Xue JL, St Peter WL, Ebben JP, Everson SE, Collins AJ. Anemia treatment in the pre-ESRD period and associated mortality in elderly patients. Am J Kidney Dis. 2002; 40: 1153-1161. Ref.: https://goo.gl/i8MsZD
Besarab A, Bolton W, Browne J, Egrie JC, Nissenson AR, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998; 339: 584-590. Ref.: https://goo.gl/ozUF3K
Mahon A, Docherty B. Renal anaemia: the patient experience. Edtna Erca J. 2004; 30: 34-37. Ref.: https://goo.gl/hFfRvG
Annual data report: atlas of end-stage renal disease in the United States. United States Renal Data System. 2007.
Carrera F, Disney A, Molina M. Extended dosing intervals with erythropoiesis-stimulating agents in chronic kidney disease: a review of clinical data. Nephrol Dial Transplant. 2007; 22. Ref.: https://goo.gl/H6atrt
Macdougall I. C.E.R.A., a once-monthly ESA: is it living up to expectations? Port J Nephrol Hypert. 2009; 23: 219-223. Ref.: https://goo.gl/ARyS17
McMurray J, Parfrey P, Adamson J, et al. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012; 2: 1-335.
Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998; 339: 584-590. Ref.: https://goo.gl/WkHRnb
Singh A, Szczech L, Tang KL, Barnhart H, Sapp S, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006; 355: 2085-2098. Ref.: https://goo.gl/hsSAow
Pfeffer M, Burdmann E, Chen CY, Cooper ME, de Zeeuw D, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009; 361: 2019-2032. Ref.: https://goo.gl/qNeqUG
Fernando C, Charmaine EL, Angel de F, Francesco Locatelli, Johannes F.E. Mann, et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: arandomized comparative trial. Nephrol Dial Transplant. 2010; 25: 4009-4017. Ref.: https://goo.gl/HYd8db
Collins A, Brenner R, Ofman JJ, Chi EM, Stuccio-White N, et al. Epoetin alfa use in patients with ESRD. An analysis of recent US prescribing patterns and hemoglobin outcomes. Am J Kidney Dis. 2005; 46: 481-488. Ref.: https://goo.gl/vUscs9